Big opportunities for small molecules in immuno-oncology (Q34487689)

2 August 2017

1 reference

title

Big opportunities for small molecules in immuno-oncology (English)

1 reference

2 August 2017

Jerry L Adams

1

1 reference

2 August 2017

James Smothers

series ordinal

2

1 reference

2 August 2017

Roopa Srinivasan

series ordinal

3

1 reference

2 August 2017

Axel Hoos

series ordinal

4

1 reference

2 August 2017

31 July 2015

1 reference

Nature Reviews Drug Discovery

2 August 2017

1 reference

2 August 2017

14

1 reference

2 August 2017

9

1 reference

2 August 2017

603-622

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd4596

2 August 2017

0 references

cites work

Inflammation and cancer: back to Virchow?

1 reference

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

21 January 2018

1 reference

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

21 January 2018

1 reference

Pembrolizumab: first global approval

21 January 2018

1 reference

In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates

21 January 2018

1 reference

Cytokines in cancer immunotherapy

21 January 2018

1 reference

Therapeutic vaccines for cancer: an overview of clinical trials

21 January 2018

1 reference

Adoptive immunotherapy for cancer: harnessing the T cell response

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.

21 January 2018

1 reference

Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies

21 January 2018

1 reference

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

21 January 2018

1 reference

Spontaneous regression of melanoma may offer insight into cancer immunology

21 January 2018

1 reference

NK cells and cancer immunosurveillance.

21 January 2018

1 reference

Immunity, Inflammation, and Cancer

21 January 2018

1 reference

Altered macrophage differentiation and immune dysfunction in tumor development

21 January 2018

1 reference

Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies

21 January 2018

1 reference

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

Induced regulatory T cells in inhibitory microenvironments created by cancer

21 January 2018

1 reference

Natural and induced T regulatory cells in cancer.

21 January 2018

1 reference

'Cancer associated fibroblasts'--more than meets the eye.

21 January 2018

1 reference

The secret ally: immunostimulation by anticancer drugs

21 January 2018

1 reference

Immunogenic cell death in cancer therapy

21 January 2018

1 reference

The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.

21 January 2018

1 reference

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

21 January 2018

1 reference

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase

21 January 2018

1 reference

Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potent inhibitors of human arginases I and II for treatment of myocardial reperfusion injury

21 January 2018

1 reference

Anti-inflammatory, antiproliferative, and cytoprotective activity of NO chimera nitrates of use in cancer chemoprevention

21 January 2018

1 reference

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.

21 January 2018

1 reference

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors

21 January 2018

1 reference

Expression of P2X7 receptor increases in vivo tumor growth

21 January 2018

1 reference

NF546 [4,4'-(carbonylbis(imino-3,1-phenylene-carbonylimino-3,1-(4-methyl-phenylene)-carbonylimino))-bis(1,3-xylene-alpha,alpha'-diphosphonic acid) tetrasodium salt] is a non-nucleotide P2Y11 agonist and stimulates release of interleukin-8 from human

21 January 2018

1 reference

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

21 January 2018

1 reference

Adenosine receptors as drug targets--what are the challenges?

21 January 2018

1 reference

Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.

21 January 2018

1 reference

ENTPD1/CD39 is a promising therapeutic target in oncology

21 January 2018

1 reference

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

21 January 2018

1 reference

The role of anti-inflammatory drugs in colorectal cancer

21 January 2018

1 reference

In vitro and in vivo characterization of PF-04418948, a novel, potent and selective prostaglandin EP₂ receptor antagonist

21 January 2018

1 reference

A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis

21 January 2018

1 reference

Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.

21 January 2018

1 reference

Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer

21 January 2018

1 reference

Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis

21 January 2018

1 reference

The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer

21 January 2018

1 reference

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

21 January 2018

1 reference

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

21 January 2018

1 reference

A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma

21 January 2018

1 reference

Challenges in outpatient end-of-life care: wishes to avoid resuscitation.

21 January 2018

1 reference

Activin receptor-like kinase5 inhibition suppresses mouse melanoma by ubiquitin degradation of Smad4, thereby derepressing eomesodermin in cytotoxic T lymphocytes

21 January 2018

1 reference

Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma

21 January 2018

1 reference

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

21 January 2018

1 reference

RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses

21 January 2018

1 reference

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

21 January 2018

1 reference

Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression.

21 January 2018

1 reference

Amino acids and immune response: a role for cysteine, glutamine, phenylalanine, tryptophan and arginine in T-cell function and cancer?

21 January 2018

1 reference

IDO expression by dendritic cells: tolerance and tryptophan catabolism

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

21 January 2018

1 reference

TGF-beta and kynurenines as the key to infectious tolerance

21 January 2018

1 reference

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

21 January 2018

1 reference

Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model.

21 January 2018

1 reference

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes

21 January 2018

1 reference

Expression patterns of the immunomodulatory enzyme arginase 1 in blood, lymph nodes and tumor tissue of early-stage breast cancer patients

21 January 2018

1 reference

Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly

21 January 2018

1 reference

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

21 January 2018

1 reference

Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma

21 January 2018

1 reference

Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma

21 January 2018

1 reference

Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer

21 January 2018

1 reference

HIF-dependent induction of adenosine receptor A2b skews human dendritic cells to a Th2-stimulating phenotype under hypoxia

21 January 2018

1 reference

T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response

21 January 2018

1 reference

Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

21 January 2018

1 reference

The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway.

21 January 2018

1 reference

CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice

21 January 2018

1 reference

High sensitivity of CD4+CD25+ regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors

21 January 2018

1 reference

ATP inhibits the generation and function of regulatory T cells through the activation of purinergic P2X receptors.

21 January 2018

1 reference

P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death

21 January 2018

1 reference

P2X(7): a growth-promoting receptor-implications for cancer

21 January 2018

1 reference

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment

21 January 2018

1 reference

P2X receptors as drug targets

21 January 2018

1 reference

Adenosine promotes alternative macrophage activation via A2A and A2B receptors

21 January 2018

1 reference

Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells

21 January 2018

1 reference

Adenosine A2B receptor blockade slows growth of bladder and breast tumors

21 January 2018

1 reference

Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates

21 January 2018

1 reference

Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.

21 January 2018

1 reference

Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients.

21 January 2018

1 reference

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death

21 January 2018

1 reference

Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness

21 January 2018

1 reference

Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39.

21 January 2018

1 reference

Therapeutic potentials of ecto-nucleoside triphosphate diphosphohydrolase, ecto-nucleotide pyrophosphatase/phosphodiesterase, ecto-5'-nucleotidase, and alkaline phosphatase inhibitors

21 January 2018

1 reference

Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases

21 January 2018

1 reference

8-BuS-ATP derivatives as specific NTPDase1 inhibitors.

21 January 2018

1 reference

Extracellular adenosine triphosphate and adenosine in cancer.

21 January 2018

1 reference

Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells

21 January 2018

1 reference

Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.

21 January 2018

1 reference

Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells

21 January 2018

1 reference

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

21 January 2018

1 reference

Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas

21 January 2018

1 reference

Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma

21 January 2018

1 reference

Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling

21 January 2018

1 reference

Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer

21 January 2018

1 reference

Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells.

21 January 2018

1 reference

Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice

21 January 2018

1 reference

Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4

21 January 2018

1 reference

The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache

21 January 2018

1 reference

Regulation of cAMP responses by the G12/13 pathway converges on adenylyl cyclase VII

21 January 2018

1 reference

Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease

21 January 2018

1 reference

Directing the immune system with chemical compounds

21 January 2018

1 reference

The Yin and Yang of Toll-like receptors in cancer

21 January 2018

1 reference

TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells

21 January 2018

1 reference

Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.

21 January 2018

1 reference

Tumor mouse model confirms MAGE-A3 cancer immunotherapeutic as an efficient inducer of long-lasting anti-tumoral responses

21 January 2018

1 reference

TLR agonists: our best frenemy in cancer immunotherapy

21 January 2018

1 reference

The chemokine superfamily revisited

21 January 2018

1 reference

Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response.

21 January 2018

1 reference

A beginner's guide to chemokines

21 January 2018

1 reference

Chemokine-chemokine receptors in cancer immunotherapy

21 January 2018

1 reference

The emerging role of CXC chemokines and their receptors in cancer

21 January 2018

1 reference

Small molecule inhibitors of CXCR4.

21 January 2018

1 reference

Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers.

21 January 2018

1 reference

Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and gr

21 January 2018

1 reference

The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma

21 January 2018

1 reference

CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis

21 January 2018

1 reference

Improving cancer immunotherapy by targeting tumor-induced immune suppression

21 January 2018

1 reference

Induction of heart valve lesions by small-molecule ALK5 inhibitors.

21 January 2018

1 reference

First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma

21 January 2018

1 reference

Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-β type I receptor kinase as cancer immunotherap

21 January 2018

1 reference

Incyte comes of age with JAK inhibitor approval.

21 January 2018

1 reference

STAT inhibitors for cancer therapy.

21 January 2018

1 reference

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

21 January 2018

1 reference

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.

21 January 2018

1 reference

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

21 January 2018

1 reference

MSP-RON signalling in cancer: pathogenesis and therapeutic potential

21 January 2018

1 reference

Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies

21 January 2018

1 reference

Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation

21 January 2018

1 reference

FOXP3+CD4+CD25+ Adaptive Regulatory T Cells Express Cyclooxygenase-2 and Suppress Effector T Cells by a Prostaglandin E2-Dependent Mechanism

21 January 2018

1 reference

A methodological framework to enhance the clinical success of cancer immunotherapy

21 January 2018

1 reference

II. Contribution to the Knowledge of Sarcoma

21 January 2018

1 reference

Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer

31 March 2020

1 reference

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

31 March 2020

1 reference

The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells

31 March 2020

1 reference

Stat3 and Gfi-1 Transcription Factors Control Th17 Cell Immunosuppressive Activity via the Regulation of Ectonucleotidase Expression

31 March 2020

1 reference

Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia

31 March 2020

1 reference

Direct Transcriptional Up-regulation of Cyclooxygenase-2 by Hypoxia-Inducible Factor (HIF)-1 Promotes Colorectal Tumor Cell Survival and Enhances HIF-1 Transcriptional Activity during Hypoxia

31 March 2020

1 reference

COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps

31 March 2020

1 reference

Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity

31 March 2020

1 reference

Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection.

31 March 2020

1 reference

Targeting regulatory T cells in tumor immunotherapy

31 March 2020

1 reference

Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptosis of tumor cells and immunization of rats

31 March 2020

1 reference

12 December 2020

High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients

1 reference

12 December 2020

The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine

1 reference

12 December 2020

Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD4596

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference